Capricor Therapeutics, Inc. (CAPR) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
10865 Road to the Cure
San Diego, CA 92121
United States of America (the)
Phone
310 358 3200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
160
First IPO Date
February 13, 2007
| Name | Title | Pay | Year Born |
| Linda Marbán | Co-Founder, President, Chief Executive Officer & Director | 580,645 | 1963 |
| Frank Isaac Litvack FACC | Executive Chairman of the Board | 120,000 | 1956 |
| Karen G. Krasney | Executive Vice President, General Counsel & Secretary | 500,718 | 1953 |
| Anthony J. Bergmann | Chief Financial Officer & Corporate Treasurer | 584,750 | 1986 |
| Kristi A. H. Elliott | Chief Operating & Science Officer | 0 | N/A |
| Mark Awadalla | Chief Development Officer | 0 | N/A |
| Minghao Sun | Senior Vice President of Quality Control, Research & Product Development | 0 | N/A |
| Nathaniel Hogan | Director of Biostatistics of Capricor Therapeutics | 0 | N/A |
| Catherine Lee Kelleher | Consultant | 0 | N/A |
| Micheal Binks | Chief Medical Officer | 0 | N/A |
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering transformative cell and exosome-based therapies to treat and prevent a diverse range of diseases and disorders. Their lead therapeutic, CAP-1002, is an allogeneic cell therapy derived from heart tissue. This candidate has successfully completed its Phase III clinical trial for patients afflicted with late-stage Duchenne muscular dystrophy (DMD). CAP-1002 is simultaneously progressing through Phase II clinical testing to address cytokine storm associated with SARS-CoV-2. Beyond CAP-1002, the company is advancing CAP-2003 through preclinical development, aiming to treat trauma-related injuries and medical conditions. Furthermore, Capricor is developing two vaccine candidates with the potential to prevent COVID-19. Capricor collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, supporting its use in DMD and other indications. The company was established in 2005 and is headquartered in San Diego, California.